Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI Interest Income

Income earned on cash, deposits, and investments held by the company.

Dyadic International, Inc.NASDAQ: DYAI

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $57.19K fell 35.3% year over year, ahead of the -44.8% change in trailing-twelve-month interest income. Sequentially, it fell 31.1% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.

Context

  • Interest income amounted to 23.1% of revenue in FY2025, up 10.0 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -35.3% holds above the trailing-twelve-month pace of -44.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$57.19K-31.1% QoQ
Last fiscal yearDec 2025
$284.09K-37.8% YoY
LTMMar 2026
$252.82K-44.8% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.3%——
1 year-37.8%——
3-year CAGR+16.3%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
284.09K USD
Year-over-year change
-37.8%
4-year CAGR
+53.1%

Interest Income vs competitors

How DYAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -44.8% is the lowest of 6, against a peer median of -3.6%.
  • Interest income amounts to 8.5% of revenue for DYAI, versus a peer median of 8.2%.
DYAI Competitors
Interest Income for DYAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANVSAnnovis Bio, Inc.LTM Mar 2026$649.25K USD+36.6%+56.4%—
ATHEAlterity Therapeutics LimitedFY2025A$446.29K AUD+66.3%+462.8%8.2%
RNXTRenovoRx, Inc.LTM Mar 2026$366K USD-19.2%+95.7%24.6%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$343.53K USD-3.6%+451.7%—
CELUCelularity Inc.LTM Dec 2025$262K USD-20.8%-10.5%1.0%
DYAIDyadic International, Inc.LTM Mar 2026$252.82K USD-44.8%+16.3%8.5%
PYPDPolyPid Ltd.LTM Mar 2026$58K USD———
VERUVeru Inc.LTM Mar 2026$0 USD———
Peer median (excluding DYAI) —-3.6%+95.7%8.2%

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.4M2.93M2.9M3.5M1.23M
Cost of Revenue1.94M2.12M1.98M1.19M2.32M
Gross Profit459.39K807.11K922.96K2.3M(1.09M)
Gross Margin19.1%27.5%31.8%65.8%-88.3%
Research & Development8.39M4.5M3.3M2.04M2.15M
Selling, General & Admin6.7M6.42M5.82M6.13M5.76M
Operating Expenses15.19M10.97M9.15M8.2M6.06M
Depreciation & Amortization3.49M038.42K00
EBITDA(11.14M)(10.12M)(8.15M)(5.38M)(6.91M)
EBITDA Margin-463.4%-345.2%-281.3%-154.0%-560.6%
Operating Income(14.73M)(10.17M)(8.23M)(5.9M)(7.15M)
Operating Margin-612.7%-346.9%-283.9%-168.8%-579.9%
Interest Income51.7K180.42K416.69K456.99K284.09K
Interest Expense000427.97K455.9K
Other Income / Expenses1.66M430.42K1.43M91.66K(218.71K)
Income Before Tax(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Pre-Tax Margin-543.7%-332.2%-234.4%-166.2%-597.6%
Income Tax Expense00000
Net Income(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Net Margin-543.7%-332.2%-234.4%-166.2%-597.6%
EPS (Basic)(0.47)(0.34)(0.24)(0.20)(0.23)
EPS (Diluted)(0.47)(0.34)(0.24)(0.20)(0.23)
Weighted Avg Shares27.84M28.36M28.8M29.32M32.62M
Weighted Avg Shares (Diluted)27.84M28.36M28.8M29.32M32.62M

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.